Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Changes in allele frequencies of CSF3R and SETBP1 mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinib.

Literature DB >> 28209656

Changes in allele frequencies of CSF3R and SETBP1 mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinib.

Zohra Nooruddin¹, Nicholas Miltgen², Qi Wei², Jeffrey Schowinsky³, Zengang Pan³, Jennifer Tobin⁴, Enkhtsetseg Purev¹, Jonathan A Gutman¹, William Robinson¹, Daniel A Pollyea⁵.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2017 PMID： 28209656 PMCID： PMC5477626 DOI： 10.3324/haematol.2016.163089

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

8 in total

1. KIT-D816V oncogenic activity is controlled by the juxtamembrane docking site Y568-Y570.

Authors: A Chaix; M-L Arcangeli; S Lopez; E Voisset; Y Yang; M Vita; S Letard; S Audebert; P Finetti; D Birnbaum; F Bertucci; M Aurrand-Lions; P Dubreuil; P De Sepulveda
Journal: Oncogene Date: 2013-02-18 Impact factor: 9.867

2. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.

Authors: M Meggendorfer; U Bacher; T Alpermann; C Haferlach; W Kern; C Gambacorti-Passerini; T Haferlach; S Schnittger
Journal: Leukemia Date: 2013-04-30 Impact factor: 11.528

3. Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia.

Authors: Maximilian Stahl; Mina L Xu; David P Steensma; Raajit Rampal; Melissa Much; Amer M Zeidan
Journal: Ann Hematol Date: 2016-04-11 Impact factor: 3.673

Review 4. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors: Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal: Blood Date: 2016-04-11 Impact factor: 22.113

5. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.

Authors: Angela G Fleischman; Julia E Maxson; Samuel B Luty; Anupriya Agarwal; Lacey R Royer; Melissa L Abel; Jason D MacManiman; Marc M Loriaux; Brian J Druker; Jeffrey W Tyner
Journal: Blood Date: 2013-09-30 Impact factor: 22.113

6. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.

Authors: Julia E Maxson; Jason Gotlib; Daniel A Pollyea; Angela G Fleischman; Anupriya Agarwal; Christopher A Eide; Daniel Bottomly; Beth Wilmot; Shannon K McWeeney; Cristina E Tognon; J Blake Pond; Robert H Collins; Basem Goueli; Stephen T Oh; Michael W Deininger; Bill H Chang; Marc M Loriaux; Brian J Druker; Jeffrey W Tyner
Journal: N Engl J Med Date: 2013-05-09 Impact factor: 91.245

7. Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia.

Authors: E K Engle; D A C Fisher; C A Miller; M D McLellan; R S Fulton; D M Moore; R K Wilson; T J Ley; S T Oh
Journal: Leukemia Date: 2014-09-25 Impact factor: 11.528

8. Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia.

Authors: Kim-Hien T Dao; Magdolna B Solti; Julia E Maxson; Elliott F Winton; Richard D Press; Brian J Druker; Jeffrey W Tyner
Journal: Leuk Res Rep Date: 2014-08-01

8 in total

13 in total

Review 1. Somatic SETBP1 mutations in myeloid neoplasms.

Authors: Hideki Makishima
Journal: Int J Hematol Date: 2017-04-26 Impact factor: 2.490

Review 2. Philadelphia-Negative Myeloproliferative Neoplasms: Laboratory Workup in the Era of Next-Generation Sequencing.

Authors: Zhuang Zuo; Shaoying Li; Jie Xu; M James You; Joseph D Khoury; C Cameron Yin
Journal: Curr Hematol Malig Rep Date: 2019-10 Impact factor: 3.952

3. Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.

Authors: Kim-Hien T Dao; Jason Gotlib; Michael M N Deininger; Stephen T Oh; Jorge E Cortes; Robert H Collins; Elliot F Winton; Dana R Parker; Hyunjung Lee; Anna Reister; Samantha Savage; Chase Brockett; Nan Subbiah; Richard D Press; Philipp W Raess; Michael Cascio; Jennifer Dunlap; Yiyi Chen; Catherine Degnin; Julia E Maxson; Cristina E Tognon; Tara Macey; Brian J Druker; Jeffrey W Tyner
Journal: J Clin Oncol Date: 2019-12-27 Impact factor: 44.544

Review 4. Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.

Authors: Kim-Hien T Dao; Jeffrey W Tyner; Jason Gotlib
Journal: Curr Hematol Malig Rep Date: 2017-10 Impact factor: 3.952

5. Targeted next-generation sequencing identifies clinically relevant mutations in patients with chronic neutrophilic leukemia at diagnosis and blast crisis.

Authors: S E Langabeer; K Haslam; J Kelly; J Quinn; R Morrell; E Conneally
Journal: Clin Transl Oncol Date: 2017-07-31 Impact factor: 3.405

Review 6. Chronic neutrophilic leukemia: new science and new diagnostic criteria.

Authors: Natasha Szuber; Ayalew Tefferi
Journal: Blood Cancer J Date: 2018-02-13 Impact factor: 11.037

7. CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival.

Authors: Natasha Szuber; Christy M Finke; Terra L Lasho; Michelle A Elliott; Curtis A Hanson; Animesh Pardanani; Ayalew Tefferi
Journal: Blood Cancer J Date: 2018-02-15 Impact factor: 11.037